A researcher's guide to preclinical mouse NASH models

S Gallage, JEB Avila, P Ramadori, E Focaccia… - Nature …, 2022‏ - nature.com
Non-alcoholic fatty liver disease (NAFLD) and its inflammatory form, non-alcoholic
steatohepatitis (NASH), have quickly risen to become the most prevalent chronic liver …

Mechanisms of NAFLD development and therapeutic strategies

SL Friedman, BA Neuschwander-Tetri, M Rinella… - Nature medicine, 2018‏ - nature.com
There has been a rise in the prevalence of nonalcoholic fatty liver disease (NAFLD),
paralleling a worldwide increase in diabetes and metabolic syndrome. NAFLD, a continuum …

[HTML][HTML] Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort☆

QM Anstee, R Darlay, S Cockell, M Meroni… - Journal of …, 2020‏ - Elsevier
Background & Aims Genetic factors associated with non-alcoholic fatty liver disease
(NAFLD) remain incompletely understood. To date, most genome-wide association studies …

[HTML][HTML] Roles of the peroxisome proliferator-activated receptors (PPARs) in the pathogenesis of nonalcoholic fatty liver disease (NAFLD)

YY Qiu, J Zhang, FY Zeng, YZ Zhu - Pharmacological Research, 2023‏ - Elsevier
Non-alcoholic fatty liver disease (NAFLD) encompasses a spectrum of disease phenotypes
which start with simple steatosis and lipid accumulation in the hepatocytes-a typical …

[HTML][HTML] Contribution of adipose tissue inflammation to the development of type 2 diabetes mellitus

MS Burhans, DK Hagman, JN Kuzma… - Comprehensive …, 2018‏ - ncbi.nlm.nih.gov
The objective of this comprehensive review is to summarize and discuss the available
evidence of how adipose tissue inflammation affects insulin sensitivity and glucose …

[PDF][PDF] Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta‐analysis

PS Dulai, S Singh, J Patel, M Soni, LJ Prokop… - …, 2017‏ - Wiley Online Library
Liver fibrosis is the most important predictor of mortality in nonalcoholic fatty liver disease
(NAFLD). Quantitative risk of mortality by fibrosis stage has not been systematically …

Non-alcoholic steatohepatitis: a review of its mechanism, models and medical treatments

C Peng, AG Stewart, OL Woodman… - Frontiers in …, 2020‏ - frontiersin.org
Non-alcoholic steatohepatitis (NASH) develops from non-alcoholic fatty liver disease
(NAFLD). Currently, around 25% of the population is estimated to have NAFLD, and 25% of …

[HTML][HTML] Liver fibrosis

MM Aydın, KC Akçalı - The Turkish Journal of Gastroenterology, 2018‏ - ncbi.nlm.nih.gov
Liver fibrosis is a wound-healing response generated against an insult to the liver that
causes liver injury. It has the potential to progress into cirrhosis, and if not prevented, it may …

SGLT-2 inhibitors in NAFLD: expanding their role beyond diabetes and cardioprotection

T Androutsakos, N Nasiri-Ansari, AD Bakasis… - International journal of …, 2022‏ - mdpi.com
Non-alcoholic fatty liver disease (NAFLD) is an 'umbrella'term, comprising a spectrum
ranging from benign, liver steatosis to non-alcoholic steatohepatitis, liver fibrosis and …

Gasdermin D plays a key role as a pyroptosis executor of non-alcoholic steatohepatitis in humans and mice

B Xu, M Jiang, Y Chu, W Wang, D Chen, X Li… - Journal of …, 2018‏ - Elsevier
Background & Aims Gasdermin D (GSDMD)-executed programmed necrosis is involved in
inflammation and controls interleukin (IL)-1β release. However, the role of GSDMD in non …